Poster Session II - A270 REAL-WORLD EFFECTIVENESS OF ABP-654 IN PATIENTS WITH INFLAMATORY BOWEL DIESEASE IN CANADA
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background ABP-654 (WEZLANA®), a biosimilar to ustekinumab (UST), was approved by Health Canada in December 2023 for several immune diseases, including Crohn’s disease (CD) and ulcerative colitis (UC). Real-world data on its use remains limited. Aims To provide initial findings on the real-world use and effectiveness of ABP-654 as the first UST biosimilar approved for use in patients with inflammatory bowel disease (IBD) across Canada Methods Data were drawn from the Adelphi IBD Disease Specific Programmen TM, a cross-sectional survey with retrospective data collection from physicians conducted in Canada from May-October 2025. Gastroenterologists (GIs) provided data on their patients with IBD receiving ABP-654, who had received >2 subcutaneous doses, including demographics, clinical characteristics, treatment utilization, and satisfaction. Analyses were descriptive. Results Seven GIs reported data on 32 patients (15 CD, 17 UC). Mean [standard deviation; SD] age was 46.3 [15.7] years and 59% of patients were male. Mean [SD] time since initiating ABP-654 therapy at the time of consultation was 8.4 [2.5] months; 29 initiated ABP-654 as first UST therapy and 3 previously received UST. At initiation of ABP-654, 94% (30/32) of patients had moderate to severe disease severity and 84% (27/32) of patients’ disease progression was deteriorating, as reported by their GI. Following ABP-654 therapy at the time of consultation, 22% (7/32) of patients had moderate to severe disease severity, and 3% (1/32) of patients’ disease progression was deteriorating (Figure 1A; Table 1). Additionally, 84% (27/32), 69% (22/32), and 84% (27/32) of patients had achieved clinical, endoscopic, and biochemical remission, respectively (Figure 1B). GIs reported they were satisfied and believed this was the best control that could be achieved for 88% (28/32) of patients (Table 1). Conclusions After ∼ 8 months of follow-up, findings from this analysis indicate that most patients receiving ABP-654, improved to mild disease, achieved remission outcomes, and GIs reported high satisfaction. Funding Agencies Amgen Inc
Institutions: Amgen (United States), Adelphi Group (United Kingdom)
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,198
OpenAlex ID: W7128767920
FWCI:
Cites:
Cited by:
Related to: